Trelegy Ellipta

About GSK plc

GSK plc is one of the world's leading pharmaceutical companies, headquartered in London, with operations in over 100 countries. The company has transformed from a traditional pharmaceutical giant into a focused biopharma company through strategic divestitures and increased R&D investment. GSK maintains leadership positions in respiratory diseases, HIV treatment, vaccines, and has a growing oncology portfolio. The company is publicly traded on the London Stock Exchange and NYSE with a market capitalization exceeding $100 billion.

About Innoviva

Innoviva operates a dual-strategy business model, generating significant royalty revenue from its legacy respiratory assets partnered with GlaxoSmithKline (GSK), including TRELEGY ELLIPTA, ANORO ELLIPTA, and RELVAR/BREO ELLIPTA. This financial foundation supports its development of a diversified pipeline in areas of high unmet need, such as oncology and infectious diseases, through subsidiaries like Innoviva Specialty Therapeutics. The company's strategic focus is on acquiring and advancing late-stage clinical assets with the potential for near-term commercialization.

Therapeutic Areas